Nicola Siragusa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nicola Siragusa has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Dell'Era
Department of Biomedical & Clinical Sciences, University of Milan, Milan, Italy, Italy
1 shared publication - Alice Scricciolo
Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, Italy
1 shared publication - Andrea Costantino
Gastroenterology and Endoscopy Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
1 shared publication - Antonio Cilona
Gastroenterology and Digestive Endoscopy Unit, Ospedale degli Infermi, ASL Biella, Biella , Italy, Italy
1 shared publication - Beatrice Rota
Center for Prevention and Diagnosis of Celiac Disease, Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Italy
1 shared publication - Carlo De Tommaso
Department of Biosciences, University of Milan, Milan, Italy, Italy
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by MDPI AG in Preprints.org
Nutritional Strategies for Managing Gastrointestinal Adverse Effects Associated with GLP-1 Receptor Agonist and Dual GIP/GLP-1 Receptor Agonist Therapy: A Narrative Review with Practical Recommendations
Incretin-based therapies have marked a turning point in the treatment of obesity, because of their demonstrated effects on body weight and beyond, including numerous cardi-ometabolic outcomes. Within obesity management, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GIP/GLP-1 RAs) are, to date, the most effective pharma-cological strategies. A growing body of evidence, however, points to limited tolerability caused by gastrointestinal adverse effects, which may impair treatment adherence and reduce both quality of life and the nutritional adequacy of patients’ diets. These effects, which include nausea, vomiting, dyspepsia, constipation, diarrhea, and abdominal bloating, are often observed in the early phases of treatment and during dose escalation. Yet the dietary recommendations available for their management remain fragmentary and inaccurate. This narrative review sets out to analyze the main pathophysiological mechanisms un-derlying the gastrointestinal manifestations of incretin-based therapies and to gather the available evidence on nutritional strategies for their prevention and management. We address the contribution of the GLP-1 and GIP systems to the modulation of gastroin-testinal motility, appetite, and clinical tolerability, with attention to the differences cur-rently recognized between selective GLP-1 RAs and dual GIP/GLP-1 RAs. We then present practical, symptom-specific recommendations covering meal distribution, mod-ulation of fat and fiber intake, hydration, food choices, and the overall quality of diet and lifestyle. Finally, we discuss the key role of nutrition in preservation adequate energy and protein intake, preventing micronutrient deficiencies, and conserving muscle mass throughout treatment with incretin-based therapies. A structured, personalized, symptom-oriented nutritional approach could improve the tolerability of these therapies, optimize clinical outcomes, and support their efficacy over the long term.
- 13 November 2026
- Published by MDPI AG in Preprints.org
Open AccessNutritional Strategies for Managing Gastrointestinal Adverse Effects Associated with GLP-1 Receptor Agonist and Dual GIP/GLP-1 Receptor Agonist Therapy: A Narrative Review with Practical Recommendations
Incretin-based therapies have marked a turning point in the treatment of obesity, because of their demonstrated effects on body weight and beyond, including numerous cardi-ometabolic outcomes. Within obesity management, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (GIP/GLP-1 RAs) are, to date, the most effective pharma-cological strategies. A growing body of evidence, however, points to limited tolerability caused by gastrointestinal adverse effects, which may impair treatment adherence and reduce both quality of life and the nutritional adequacy of patients’ diets. These effects, which include nausea, vomiting, dyspepsia, constipation, diarrhea, and abdominal bloating, are often observed in the early phases of treatment and during dose escalation. Yet the dietary recommendations available for their management remain fragmentary and inaccurate. This narrative review sets out to analyze the main pathophysiological mechanisms un-derlying the gastrointestinal manifestations of incretin-based therapies and to gather the available evidence on nutritional strategies for their prevention and management. We address the contribution of the GLP-1 and GIP systems to the modulation of gastroin-testinal motility, appetite, and clinical tolerability, with attention to the differences cur-rently recognized between selective GLP-1 RAs and dual GIP/GLP-1 RAs. We then present practical, symptom-specific recommendations covering meal distribution, mod-ulation of fat and fiber intake, hydration, food choices, and the overall quality of diet and lifestyle. Finally, we discuss the key role of nutrition in preservation adequate energy and protein intake, preventing micronutrient deficiencies, and conserving muscle mass throughout treatment with incretin-based therapies. A structured, personalized, symptom-oriented nutritional approach could improve the tolerability of these therapies, optimize clinical outcomes, and support their efficacy over the long term.